Manteinance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria
- Resource Type
- Authors
- Paola Arbo; Riccardo Giunta; Ciro Romano; Umberto De Fanis; Gaetano Esposito; Giacomo Lucivero; Ausilia Sellitto
- Source
- Subject
- Pulmonary and Respiratory Medicine
Long lasting
medicine.medical_specialty
business.industry
Immunology
Low dose
Drug resistance
Omalizumab
Gastroenterology
CHRONIC URTICARIA
Chronic disease
OMALIZUMAB
Refractory
Internal medicine
Monoclonal
medicine
Immunology and Allergy
business
Chronic urticaria
medicine.drug
- Language
- English
Omalizumab, an anti-IgE monoclonal antibody, is increasingly being used in diseases other than allergic asthma. We report on the successful long-term management of refractory chronic urticaria in 2 patients using low-dose omalizumab.